Lin Y, Berdeja J, Raje N, et al. First-in-human multicenter study of BB2121 anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma: updated results. EHA 2017, abstract 142.
Nieuw kostenmodel brengt economische impact van DLBCL in Nederland in kaart
jan 2026 | Lymfoom